Biomarker Card
This biomarker card gives comprehensive information about each biomarker.
Detailed Information | |
---|---|
Biomarker ID | 1891 |
PMID | 30641210 |
Year | 2019 |
Biomarker | Interleukin 8 [SNP: rs4073 AA vs. TA+TT] |
Biomarker Basis | Mutation Based |
Biomolecule | Mutation |
Source | Blood |
Subjects | Humans |
Regulation | Downregulated in PCa: [4-(3,4-dihydro-2,2,4-trimethyl-2H-1-benzopyran-4-yl)-phenol; Estradiol; Ethyl à-hydroxymyristate trisiloxane; 1-(2,4-Dimethylphenyl)-3-(tetrahydrofuryl-2)propane; 2-amino-Imidazole-5-carboxylic acid; ] Upregulated in PCa: [1,1,3,3,5,5,7,7,9,9-decamethyl-pentasiloxane; 1,1,1,5,5,5-hexamethyl-3,3-bis[(trimethylsilyl)oxy]-Trisiloxane; Phthalic acid, bis(7-methyloctyl) ester; 4-Nitro-4’-chlorodiphenylsulfoxide; 1-Propylpentachlorotriphosphazene; 2,6-di-t-butyl-4-hydroxymethylene-2,3,5,6-detetrahydrocyclohexanone] |
Odds Ratio/Hazard Ratio/Relative Risk | OR: 0.58 (95% CI: 0.35–0.96) |
Effect on Pathways | NA |
Experiment | Prostate Cancer Vs Benign Prostatic hyperplasia |
Type of Biomarker | Diagnostic/Prognostic |
Cohort | 530 individuals including 130 PCa patients, 200 BPH patients and 200 male controls were selected for the study |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p=0.03 |
Method Used | ARMS-PCR |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | NA |